Completed PHASE2 INTERVENTIONAL 1-arm NCT03659578

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

A Phase II Study of Thymopeptide a1 During Split-course Chemoradiotherapy to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

Sponsor: Sun Yat-sen University

Conditions Non-small Cell Lung Cancer

Interventions Concurrent chemotherapy split-course radiotherapy thymosin alpha 1

Updated 6 times since 2018 Last updated: Dec 30, 2021 Started: Aug 9, 2018 Primary completion: Sep 30, 2021 Completion: Sep 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-small Cell Lung Cancer, this trial is completed. The trial is conducted by Sun Yat-sen University and has accumulated 6 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2021 — Jan 2022 [monthly]

Unknown Status PHASE2
Oct 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Oct 2018 — Oct 2020 [monthly]

Recruiting PHASE2

First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China